A Randomized, Open-label, Multiple Dosing, 3-way Crossover Study to Evaluate the Drug-drug Interaction Between Atorvastatin and Fenofibric Acid in Healthy Male Volunteers

Chong Kun Dang Pharmaceutical1 个研究点分布在 1 个国家目标入组 30 人开始时间: 2015年3月17日最近更新: 2017年8月8日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方: Chong Kun Dang Pharmaceutical
入组人数: 30
试验地点: 1
主要终点: Atorvastatin and Fenofibric acid AUCτ

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to evaluate the pharmacokinetic interaction between Atorvastatin and Fenofibric acid.

详细描述

This study is a randomized, open-label, multiple dosing, 3-way crossover design to evaluate the drug-drug interaction between Atorvastatin (Lipitor) and Fenofibric (Trilipix) acid in healthy male subjects. Subjects will receive repeated dose of Atorvastatin (40mg*1Tab/day) or Fenofibric acid (135mg*1Cap/day) or Atorvastatin (40mg*1Tab/day)/Fenofibric acid (135mg*1Cap/day). Each treatment period was separated by a washout period of at least 8 days.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Crossover
主要目的: Treatment
盲法: None

入排标准

年龄范围: 19 Years 至 —（Adult, Older Adult）
性别: Male
接受健康志愿者: 是

入选标准

•Healthy man older than 19 years at the time of screening.
•BMI more than 17.5kg / m2 and less than 30.5kg / m2 and weight more than 55kg
•Subject without congenital or chronic diseases and no psychotic symptoms or findings from the medical examination.
•Suitable subject who is determined by laboratory tests such as hematology tests, blood chemistry, urinalysis test according to the characteristics of the drug and screening tests such as ECG test.
•Subject who fully understand the clinical trials after in-depth explanation given prior to the clinical study, decided to join the clinical trials by their will and signed consent form which approved by Chonbuk National University Hospital IRB.
•Subjects who are able to comply with all scheduled visits, laboratory tests and other procedures.

排除标准

•Subject who has a history of blood, kidneys, endocrine, respiratory, gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurological or allergic diseases that is clinically significant (Except untreated asymptomatic seasonal allergies at the time of administration)
•Subject who has a history of gastrointestinal disease or gastrointestinal surgery which can affect drug absorption.
•Showing the value that corresponds to following laboratory parameters: AST or AST or CK > 2* upper limit of normal range.
•Alcohol > 210g/week, within 6 months prior to the screening.
•Taking the medication involved in other clinical trials within two months before the first dose medication characters.
•Sitting Systolic Blood Pressure ≥ 140 mmHg, Diastolic Blood Pressure ≥ 90 mmHg at the time of screening.
•History of alcohol or drug abuse, within 1 year
•Subjects who treated with metabolizing enzyme inducers or inhibitors such as barbitals within 30days prior to the first dosing.
•Smoker (> 20cigarettes/day)
•Subjects who takes ETC or OTC medicine within 10days before the first IP administration.
•Subject who done the whole blood donation within two months or component blood donation within 1 month within 1 month prior to the first dosing.
•Subject who can increase risk due to clinical test and administration of drugs or has Severe grade / chronic medical, mental condition or abnormal laboratory result that may interfere with the analysis of test results.
•Subject with serious history of hypersensitivity or allergy to investigational product.
•Active liver disease.
•Muscle disease.
•Subject with genetic problems such as galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption.
•Patients with severe hepatic impairment or Gallbladder Disease.
•Patients with moderate to severe renal impairment.
•Patients experienced allergy or phototoxicity during treatment with fibrate or ketoprofen.
•Subjects who is not able to comply with guidelines described in the protocol.
•Subjects who is determined by investigator's decision as unsuitable for clinical trial participation.

研究组 & 干预措施

Group1: TreatmentA+TreatmentB+TreatmentC

Experimental

TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.